Inhibition of the G protein-coupled receptor (GPCR) adenosine A2A receptor (A2AR) has been proposed as a strategy for preventing immunosuppression by extracellular adenosine in the tumor microenvironment [7]. The gene discussed is ADORA2A; the disease is neoplasm.